PURPOSE: An estimated 24%-45% of patients with cancer develop brain metastases. Individualized estimation of survival for patients with brain metastasis could be useful for counseling patients on clinical outcomes and prognosis. METHODS: De-identified data for 2367 patients with brain metastasis from 7 Radiation Therapy Oncology Group randomized trials were used to develop and internally validate a prognostic nomogram for estimation of survival among patients with brain metastasis. The prognostic accuracy for survival from 3 statistical approaches (Cox proportional hazards regression, recursive partitioning analysis [RPA], and random survival forests) was calculated using the concordance index. A nomogram for 12-month, 6-month, and median survival was generated using the most parsimonious model. RESULTS: The majority of patients had lung cancer, controlled primary disease, no surgery, Karnofsky performance score (KPS) ≥ 70, and multiple brain metastases and were in RPA class II or had a Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) score of 1.25-2.5. The overall median survival was 136 days (95% confidence interval, 126-144 days). We built the nomogram using the model that included primary site and histology, status of primary disease, metastatic spread, age, KPS, and number of brain lesions. The potential use of individualized survival estimation is demonstrated by showing the heterogeneous distribution of the individual 12-month survival in each RPA class or DS-GPA score group. CONCLUSION: Our nomogram provides individualized estimates of survival, compared with current RPA and DS-GPA group estimates. This tool could be useful for counseling patients with respect to clinical outcomes and prognosis.
PURPOSE: An estimated 24%-45% of patients with cancer develop brain metastases. Individualized estimation of survival for patients with brain metastasis could be useful for counseling patients on clinical outcomes and prognosis. METHODS: De-identified data for 2367 patients with brain metastasis from 7 Radiation Therapy Oncology Group randomized trials were used to develop and internally validate a prognostic nomogram for estimation of survival among patients with brain metastasis. The prognostic accuracy for survival from 3 statistical approaches (Cox proportional hazards regression, recursive partitioning analysis [RPA], and random survival forests) was calculated using the concordance index. A nomogram for 12-month, 6-month, and median survival was generated using the most parsimonious model. RESULTS: The majority of patients had lung cancer, controlled primary disease, no surgery, Karnofsky performance score (KPS) ≥ 70, and multiple brain metastases and were in RPA class II or had a Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) score of 1.25-2.5. The overall median survival was 136 days (95% confidence interval, 126-144 days). We built the nomogram using the model that included primary site and histology, status of primary disease, metastatic spread, age, KPS, and number of brain lesions. The potential use of individualized survival estimation is demonstrated by showing the heterogeneous distribution of the individual 12-month survival in each RPA class or DS-GPA score group. CONCLUSION: Our nomogram provides individualized estimates of survival, compared with current RPA and DS-GPA group estimates. This tool could be useful for counseling patients with respect to clinical outcomes and prognosis.
Authors: Felix K-H Chun; Thomas Steuber; Andreas Erbersdobler; Eike Currlin; Jochen Walz; Thorsten Schlomm; Alexander Haese; Hans Heinzer; Michael McCormack; Hartwig Huland; Markus Graefen; Pierre I Karakiewicz Journal: Eur Urol Date: 2005-12-22 Impact factor: 20.096
Authors: Gregory M M Videtic; David J Adelstein; Tarek M Mekhail; Thomas W Rice; Glen H J Stevens; Shih-Yuan Lee; John H Suh Journal: Int J Radiat Oncol Biol Phys Date: 2006-10-23 Impact factor: 7.038
Authors: Thomas Steuber; Felix K-H Chun; Andreas Erbersdobler; Alberto Briganti; Alexander Haese; Markus Graefen; Thorsten Schlomm; Luc Valiquette; Hartwig Huland; Pierre I Karakiewicz Journal: Urology Date: 2006-12-04 Impact factor: 2.649
Authors: Andrea Gallina; Felix K-H Chun; Alberto Briganti; Shahrokh F Shariat; Francesco Montorsi; Andrea Salonia; Andreas Erbersdobler; Patrizio Rigatti; Luc Valiquette; Hartwig Huland; Markus Graefen; Pierre I Karakiewicz Journal: Eur Urol Date: 2007-01-22 Impact factor: 20.096
Authors: Pierre I Karakiewicz; Serge Benayoun; Michael W Kattan; Paul Perrotte; Luc Valiquette; Peter T Scardino; Ilias Cagiannos; Hans Heinzer; Simon Tanguay; Armen G Aprikian; Hartwig Huland; Markus Graefen Journal: J Urol Date: 2005-06 Impact factor: 7.450
Authors: K J Murray; C Scott; H M Greenberg; B Emami; M Seider; N L Vora; C Olson; A Whitton; B Movsas; W Curran Journal: Int J Radiat Oncol Biol Phys Date: 1997-10-01 Impact factor: 7.038
Authors: Lawrence Berk; Brian Berkey; Tyvin Rich; William Hrushesky; David Blask; Michael Gallagher; Mahesh Kudrimoti; Ronald C McGarry; John Suh; Minesh Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2007-04-06 Impact factor: 7.038
Authors: Peter Baumgarten; Johanna Quick-Weller; Florian Gessler; Marlies Wagner; Julia Tichy; Marie-Therese Forster; Christian Foerch; Volker Seifert; Michel Mittelbronn; Christian Senft Journal: J Neurooncol Date: 2018-05-24 Impact factor: 4.130
Authors: Paul J Black; Brandi R Page; John T Lucas; Ryan T Hughes; Adrian W Laxton; Stephen B Tatter; Michael T Munley; Michael D Chan Journal: J Radiosurg SBRT Date: 2015
Authors: Thomas Spanberger; Anna S Berghoff; Carina Dinhof; Aysegül Ilhan-Mutlu; Manuel Magerle; Markus Hutterer; Josef Pichler; Adelheid Wöhrer; Monika Hackl; Georg Widhalm; Johannes A Hainfellner; Karin Dieckmann; Christine Marosi; Peter Birner; Daniela Prayer; Matthias Preusser Journal: Clin Exp Metastasis Date: 2012-10-17 Impact factor: 5.150
Authors: Rupesh Kotecha; Sally Vogel; John H Suh; Gene H Barnett; Erin S Murphy; Chandana A Reddy; Michael Parsons; Michael A Vogelbaum; Lilyana Angelov; Alireza M Mohammadi; Glen H J Stevens; David M Peereboom; Manmeet S Ahluwalia; Samuel T Chao Journal: J Neurooncol Date: 2016-07-25 Impact factor: 4.130